Aurobindo Pharma, a major pharmaceutical company in India, has announced a share buyback program totaling ₹800 crore (approximately $96 million USD) through a tender offer. The buyback is scheduled to open on April 23 and close on April 29, with a record date for eligible shareholders set for April 17. The company plans to repurchase up to 54.23 lakh shares at a price of ₹1,475 per share, which constitutes about 0.93% of its total outstanding shares.

The buyback aims to provide better participation for retail investors, with small shareholders receiving a higher acceptance ratio—7 shares for every 61 held in the reserved category and 2 shares for every 249 held in the general category. This structure is designed to enhance retail investor engagement, although the final acceptance will depend on overall subscription levels.

While the buyback size indicates a modest reduction in share capital, it signals Aurobindo Pharma's intent for capital allocation and potential surplus cash deployment. The company’s choice of a tender offer over an open market buyback offers price certainty but may result in proportional acceptance of tendered shares. Investors will be monitoring the buyback price against the current market price for potential arbitrage opportunities.